Analysts’ Recent Ratings Changes for Dermira (DERM)

Dermira (NASDAQ: DERM) has recently received a number of price target changes and ratings updates:

  • 5/14/2019 – Dermira was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 5/8/2019 – Dermira was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 5/8/2019 – Dermira had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.””
  • 5/7/2019 – Dermira was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 5/4/2019 – Dermira was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 5/3/2019 – Dermira had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock. They wrote, “DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25.””
  • 4/23/2019 – Dermira was given a new $22.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 4/18/2019 – Dermira had its price target raised by analysts at Cantor Fitzgerald to $25.00. They now have an “overweight” rating on the stock.
  • 4/16/2019 – Dermira was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 4/3/2019 – Dermira was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 4/2/2019 – Dermira had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock. They wrote, “. We are reiterating our OW rating and 12 month PT of $20 for DERM shares post its equity raise. The raise gives DERM the funds needed to: 1) continue the commercialization of R&D as well as commercialization of product candidates, including for working capital, capex and other corporate purposes. The next catalyst is likely to be Almirall’s (Not Covered) exercise of its EU option for Lebrikzumab. Also, physicians we have spoken with after the positive Phase 2b Lebrikizumab data underscore a place for it in the market given its safety and efficacy. Finally, we continue to think DERM is an interesting asset in a consolidating space.””
  • 3/28/2019 – Dermira was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 3/27/2019 – Dermira had its price target raised by analysts at HC Wainwright from $13.00 to $22.00. They now have a “buy” rating on the stock.
  • 3/25/2019 – Dermira had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock, up previously from $16.00.

Shares of Dermira stock opened at $9.72 on Friday. Dermira Inc has a one year low of $6.00 and a one year high of $15.48. The company has a market cap of $522.21 million, a P/E ratio of -1.85 and a beta of 1.32. The company has a current ratio of 7.13, a quick ratio of 6.92 and a debt-to-equity ratio of 4.36.

Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%. The company had revenue of $2.45 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, research analysts predict that Dermira Inc will post -5.2 earnings per share for the current year.

In related news, insider Eugene A. Bauer sold 35,000 shares of Dermira stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.00, for a total transaction of $525,000.00. Following the transaction, the insider now owns 43,900 shares in the company, valued at $658,500. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 14.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Fifth Third Bancorp purchased a new position in Dermira during the first quarter worth approximately $44,000. Advisor Group Inc. lifted its position in Dermira by 117.0% during the first quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 3,269 shares in the last quarter. HighTower Advisors LLC raised its position in Dermira by 32.0% in the first quarter. HighTower Advisors LLC now owns 17,244 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,181 shares during the period. Northern Trust Corp raised its position in Dermira by 1.6% in the first quarter. Northern Trust Corp now owns 439,374 shares of the biopharmaceutical company’s stock valued at $5,954,000 after purchasing an additional 7,103 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in Dermira by 48,273.3% in the first quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 7,241 shares during the period. Hedge funds and other institutional investors own 83.38% of the company’s stock.

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

See Also: Green Investing

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.